TENX - Tenax Therapeutics, Inc. Net Sales Margin

Tenax Therapeutics, Inc. - graphic logo of issuer TENX

Actual sales margins demonstrate the financial dependence of Tenax Therapeutics (TENX) on government procurement and insurance reimbursements within the cardiology sector. Currently, 0.00 represents the current metric value. The company is optimizing costs by outsourcing the final stages of clinical trials to external CRO partners. Growth is anchored by the patent for Levosimendan, a unique drug for the therapy of pulmonary hypertension without oxygen stress.

Tenax Therapeutics Inc (TENX) Net Profit Margin: for the period 07/04/2022 - 11/20/2026

TENX (Tenax Therapeutics): analytical breakdowns and indicator data

- market value and analyst target forecast:
Fundamental company valuation:Tenax Therapeutics Inc. - TENX
Finished products of Tenax Therapeutics Inc

Sales margins determine the share of net profit in each unit of revenue, stripping market noise from the analysis. This ratio measures the actual efficiency of capital generation after all expenses. By analyzing the target net margin, an investor can see the impact of geopolitical risks on the cost of raw materials and patents for Tenax Therapeutics (TENX). Supply chain disruptions and sanctions directly reduce final profitability, allowing for an objective assessment of investment capital stability.